Outlook Therapeutics (OTLK) catalysts

FreeBioList has 1 catalyst on record for Outlook Therapeutics (OTLK, listed on Nasdaq), all now decided. It concerns ONS-5010 / LYTENAVA (bevacizumab-vikg) (Wet age-related macular degeneration).

Decided and on record:

• ONS-5010 / LYTENAVA (bevacizumab-vikg), PDUFA date: Approved 24 July 2026, five days ahead of the PDUFA date.

Each outcome links to the filing or notice that reported it in the table below.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 14 Sep 2026. The methodology page explains each status.

Background reading: What a PDUFA date is, and why the FDA doesn't publish them.